Clinical Trials Logo

Urolithiasis clinical trials

View clinical trials related to Urolithiasis.

Filter by:

NCT ID: NCT05460247 Recruiting - Clinical trials for Kidney Stone Prevention

Protein Sources Urinary Stone Risk

Start date: October 30, 2022
Phase: N/A
Study type: Interventional

Prior studies have shown that the source of dietary protein can have a significant impact on urinary stone risk. However, whey and plant protein isolates have not been compared. This is an important distinction as protein supplements fortified foods are increasingly popular. Herein, we seek to investigate the effect of different protein supplements, in an otherwise identical diet, on urinary stone risk.

NCT ID: NCT05452291 Recruiting - Urolithiasis Clinical Trials

Multiomics Biomarkers for Urolithiasis

Start date: May 27, 2022
Phase:
Study type: Observational

This is a prospective case series study. To compare urine sample of recurrent stone-formers and non-stone former by multiomics approach to identify potential markers for stone recurrence.

NCT ID: NCT05443932 Not yet recruiting - Urolithiasis Clinical Trials

Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

Start date: March 4, 2024
Phase: Phase 4
Study type: Interventional

Current prevention strategies in patients with recurrence of kidney stones show especially in high-risk patients a diversely and in the long-term not successful outcome in a sustainable number of cases. Recent studies have revealed that Dapagliflozin has the potential to decrease risk and incidence of urolithiasis events especially in patients suffering from Diabetes. The investigators propose that Dapagliflozin has the potential to increase the metabolic situation of hyperoxaluric patients with recurrence of urolithiasis. The investigators therefore test whether Dapagliflozin can decrease the oxalate excretion compared to the current strategy with Hydrochlorothiazide. The study may open up a new way of preventing urolithiasis in patients with high-risk of recurring urolithiasis.

NCT ID: NCT05340088 Completed - Urolithiasis Clinical Trials

Optimal Passive Dilation Time in Retrograde Intrarenal Surgery

Start date: September 1, 2021
Phase:
Study type: Observational

Retrograde intrarenal surgery (RIRC) is used as standard treatment for stones less than 2 cm. In some cases, the ureteral access sheath cannot be placed due to ureteral stricture. In this case, a double j stent (DJ) is placed to passively dilate the ureter, and the RIRC is postponed for post-dilatation. The aim of the study is to determine the optimal time for RIRC operation in cases where a double j stent was placed for passive dilatation.

NCT ID: NCT05340075 Completed - Urolithiasis Clinical Trials

Staged Bilateral Percutaneous Nephrolithotomy

Start date: September 15, 2021
Phase:
Study type: Observational

To determine the optimal time between the first and second operations in patients with bilateral kidney stones and scheduled percutaneous nephrolithotomy for the contralateral kidney. Patients who underwent percutaneous nephrolithotomy to the contralateral kidney 2-4 weeks and 4-6 weeks after the first operation will be compared.

NCT ID: NCT05329389 Recruiting - Urolithiasis Clinical Trials

Adherence to Fluid Intake Recommendations in Kidney Stone Patients

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The cumulative risk of stone recurrence rate is up to 14% at 1 year, 35% at 5 years, and 52% at 10 years. Low urine volume caused by insufficient fluid consumption is one of the most crucial risk factors for kidney stone formation. According to the guidelines, a copious fluid intake to maintain a urine volume of at least 2.0 to 2.5 L/24 h is recommended for most kidney stone formers. Patients often find it difficult to follow the recommendations in fluid intake, which leads to stone recurrence. Therefore, there is a need to improve patient compliance and adherence to following the instructions on keeping water balance. For this purpose we developed a mixed educational program including two parts. The first is the mobile application called "StoneMD: Kidney Stones". The second is the "School for Patients" with kidney stones, which is responsible for the stone clinic effect.

NCT ID: NCT05297331 Recruiting - Urolithiasis Clinical Trials

Perioperative Parameter and Treatment Outcomes of Urinary Calculi in Hong Kong

Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

This is a prospective data registry to assess the treatment outcomes and complications of different treatment approaches for different surgical treatment of urolithiasis in our hospital clusters.

NCT ID: NCT05293262 Completed - COVID-19 Clinical Trials

Endourological Management of Stones During COVID19

Start date: January 23, 2020
Phase:
Study type: Observational

Guidelines for endourological procedures during COVID-19 have suggested deferring all elective procedures, while obstructed/ infected stones should undergo urgent decompression. At our centre, screening protocols were implemented with prioritization strategies so that elective care could safely continue at deescalated rates. COVID or septic patients underwent emergency decompression, while non-COVID and non-septic patients underwent primary ureteroscopy (URS) or retrograde intrarenal surgery (RIRS). We aim to report our experience with endourological surgery for stone disease during COVID-19.

NCT ID: NCT05270421 Recruiting - Urolithiasis Clinical Trials

Effect of Furosemide on ESWL Outcomes for Renal and Ureteral Calculi

Start date: July 1, 2020
Phase: Phase 3
Study type: Interventional

The minimally-invasive extracorporeal shockwave lithotripsy (ESWL) procedure is generally considered the best first-line treatment option for most adults and children with nephrolithiasis, especially when the calculi are smaller than 2 cm in size. Despite some promising results, few clinical trials have assessed the impact of furosemide on the outcome of ESWL. This study seeks to determine the effect of furosemide on ESWL outcomes when treating renal and ureteral calculi, hypothesizing that it will result in better outcomes for patients. The present double-blind, randomized clinical trial includes 500 adults aged 18-60 years referring to the ESWL Clinic of Shahid Faghihi Hospital. Using block randomization, the patients are randomly assigned to one of two groups. All patients are to receive sedation with intravenous midazolam and 1000 ml of normal saline 30 minutes before ESWL. The only difference between the groups is that in the furosemide group, 40 mg of furosemide is added to the normal saline in the drug preparation room before administration. All patients are kept under heart monitoring and pulse oximetry until recovery. Pain will be checked for all participants via a telephone interview 24 hours later. The outcomes and possible side effects of ESWL will be evaluated for all patients after two and twelve weeks.

NCT ID: NCT05201599 Recruiting - Urinary Calculi Clinical Trials

Treatment of Upper Urinary Tract Stones With a Diameter≤2cm by Intelligent Pressure-controlled Flexible Ureteroscope

Start date: August 11, 2021
Phase: N/A
Study type: Interventional

The aim of this trial is to compare the efficacy and safety of flexible ureteroscope with intelligent control of renal pelvic pressure (FURL-ICP) and traditional flexible ureteroscope(f-URL) in the treatment of upper urinary stones ≤ 2cm in diameter. It is designed as a multicenter, parallel randomized controlled trial with two arms. At least 449 patients with upper urinary stones ≤ 2cm in diameter will be invited to participant in this study. Patients will be assigned to intervention group (FURL-ICP group) or control group (f-URL) by a simple random sampling technique with a rate of 1:1. The baseline of participants include demographic data, urine analysis, blood cell analysis, blood biochemical analysis, and urinary computer tomography (CT) with a slice thickness of 2mm. The primary outcomes are postoperative stone-free rate (SFR) of one month by CT scan and postoperative fever rate (body temperature > 38.5 ℃ within 3 days after operation). Secondary outcomes include operating time, degree of ureteral injury, SFR of one day.